Second Generation, WHO Country Cooperation Strategy, 2010–2015, Namibia
National Tuberculosis and Leprosy Conrol Programme
Treating the Patient with Tuberculosis
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
WHO/CDS/CSR/EDC/99.2 Plague Manual
Epidemiology, Distribution, Surveillance and Control
Therapeutics Information and Pharmacovigilance Centre | TIPC
Doc. No.: INS/GDL/001-(Annexes)
HRH SA 2030 | Draft HR Strategy for the Health Sector: 2012/13 – 2016/17 Consultation Document
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Framework for implementation.
The END TB Strategy.